Non-resection techniques for correcting type II mitral regurgitation by A. Carpentier ; Нерезекционные методики коррекции митральной недостаточности II типа по А. Carpentier

Συγγραφείς: V. V. Evtushenko, A. N. Zhilina, E. N. Pavlyukova, A. V. Evtushenko, В. В. Евтушенко, А. Н. Жилина, Е. Н. Павлюкова, А. В. Евтушенко

Συνεισφορές: the study was carried out within the framework of the applied scientific topic of Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russia)., Исследование выполнено в рамках прикладной научной темы ОССХ НИИ кардиологии Томского НИМЦ

Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 40, № 1 (2025); 103-109 ; Сибирский журнал клинической и экспериментальной медицины; Том 40, № 1 (2025); 103-109 ; 2713-265X ; 2713-2927

Θεματικοί όροι: разрыв политетрафторэтиленовой хорды, chordal transposition, non-resection techniques, mitral valve reconstruction, mitral valve insufficiency, mitral valve prolapse, mitral regurgitation, long-term outcomes, rupture of polytetrafluoroethylene chordae, транслокация хорд, нерезекционные методики, реконструкция митрального клапана, недостаточность митрального клапана, пролапс митрального клапана, митральная регургитация, долгосрочные результаты

Περιγραφή αρχείου: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/2638/1053; Wu S., Chai A., Arimie S., Mehra A., Clavijo L., Matthews R.V. et al. Incidence and treatment of severe primary mitral regurgitation in contemporary clinical practice. Cardiovasc. Revasc. Med. 2018;19(8):960–963. https://doi.org/10.1016/j.carrev.2018.07.021; Pype L.L., Bertrand P.B., Debonnaire P., Dhont S., Hoekman B., Paelinck B.P. et al. Mitral valve surgery for mitral regurgitation results in reduced left ventricular ejection fraction in Barlow's disease as compared with fibro-elastic deficiency. J. Cardiovasc. Dev. Dis. 2024;11(3):71. https://doi.org/10.3390/jcdd11030071; Ronco D., Buttiglione G., Garatti A., Parolari A. Biology of mitral valve prolapse: from general mechanisms to advanced molecular patterns – a narrative review. Front. Cardiovasc. Med. 2023;10:1128195. https://doi.org/10.3389/fcvm.2023.1128195; Desai M.Y., Grigioni F., Di Eusanio M., Saccocci M., Taramasso M., Maisano F. et al. Outcomes in degenerative mitral regurgitation: Current state-of-the art and future directions. Prog. Cardiovasc. Dis. 2017;60(3):370–385. https://doi.org/10.1016/j.pcad.2017.10.005; Евтушенко В.В., Макогончук И.С., Евтушенко А.В. Правила и принципы отбора пациентов на хирургическое лечение приобретенных пороков сердца, осложненных фибрилляцией предсердий. Сибирский журнал клинической и экспериментальной медицины. 2017;32(3):29–34. https://doi.org/10.29001/2073-8552-2017-32-3-29-34; Meier S., Seeburger J., Borger M.A. Advances in mitral valve surgery. Curr. Treat Options Cardiovasc. Med. 2018;20(9):75. https://doi.org/10.1007/s11936-018-0666-3; De Bonis M., Alfieri O., Dalrymple-Hay M., Del Forno B., Dulguerov F., Dreyfus G. Mitral valve repair in degenerative mitral regurgitation: State of the art. Prog. Cardiovasc. Dis. 2017;60(3):386–393. https://doi.org/10.1016/j.pcad.2017.10.006; Di Mauro M., Bonalumi G., Giambuzzi I., Messi P., Cargoni M., Paparella D. et al. Mitral valve repair with artificial chords: Tips and tricks. J. Card. Surg. 2022;37(12):4081–4087. https://doi.org/10.1111/jocs.17076; Макогончук И.С., Евтушенко В.В., Евтушенко А.В. Клинические и фундаментальные аспекты протезирования и транслокации хорд митрального клапана. Сибирский журнал клинической и экспериментальной медицины. 2018;33(1):27–32. https://doi.org/10.29001/2073-8552-2018-33-1-27-32; Elde S., Woo Y.J. Neochords: How long, how many, too many? JTCVS Tech. 2023;22:59–64. https://doi.org/10.1016/j.xjtc.2023.10.018; Montanhesi P.K., Ghoneim A., Gelinas J., Chu M.W.A. Simplifying mitral valve repair: A guide to neochordae reconstruction. Innovations. 2022;17(4):343–351. https://doi.org/10.1177/15569845221115186; Loardi C., Zanobini M. Unsatisfying mitral valve repair? The “Loop method”: a lifebelt to grab. J. Cardiothorac. Surg. 2021;16(1):269. https://doi.org/10.1186/s13019-021-01649-x; Park M.H., Marin-Cuartas M., Imbrie-Moore A.M., Wilkerson R.J., Pandya P.K., Zhu Y. et al. Biomechanical analysis of neochordal repair error from diastolic phase inversion of static left ventricular pressurization. JTCVS Tech. 2022;12:54–64. https://doi.org/10.1016/j.xjtc.2022.01.009; Идов Э.М., Хубулава Г.Г., Шихвердиев Н.Н., Марченко С.П., Кальной П.C., Бодров Д.А. Экспериментальное исследование механических свойств митрального клапана при дегенеративной патологии. Клиническая и экспериментальная хирургия. 2015;3(9):18–24. EDN: UNAGWX; https://www.sibjcem.ru/jour/article/view/2638

Διαθεσιμότητα: https://www.sibjcem.ru/jour/article/view/2638
https://doi.org/10.29001/2073-8552-2025-40-1-103-109

Sequelae of COVID-19 at long-term follow-up after hospitalization ; Последствия COVID-19 на отдаленном этапе после госпитализации

Συγγραφείς: N. V. Pogosova, F. N. Paleev, A. K. Ausheva, D. T. Kuchiev, S. A. Gaman, T. N. Veselova, M. B. Belkind, O. Yu. Sokolova, R. A. Zhetisheva, S. K. Ternovoy, S. A. Boytsov, Н. В. Погосова, Ф. Н. Палеев, А. К. Аушева, Д. Т. Кучиев, С. А. Гаман, Т. Н. Веселова, М. Б. Белькинд, О. Ю. Соколова, Р. А. Жетишева, С. К. Терновой, С. А. Бойцов

Συνεισφορές: The study was performed with the support of the National Medical Research Center of Cardiology named after Academician E.I.Chazov., Исследование проведено при поддержке Национального медицинского исследовательского центра кардиологии имени Академика Е.И. Чазова.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 2 (2022); 118-126 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 2 (2022); 118-126 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: компьютерная томография, long-term sequelae, clinical features, outcomes, death, computed tomography, долгосрочные результаты, клинические характеристики, исходы, смерть

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2705/2292; https://www.rpcardio.com/jour/article/view/2705/2309; Ghebreyesus TA. WHO Director-General's opening remarks at the media briefing on COVID-19. 11 March 2020 [cited 2022 Jan 10]. Available from: https://www.who.int/ru/directorgeneral/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid19---11-march-2020.; WHO Coronavirus (COVID-19) Dashboard [cited 2022 Jan 10]. Available from: https://covid19.who.int/.; Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. DOI:10.1016/S0140-6736(20)30183-5.; Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. DOI:10.1001/jama.2020.2648.; Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531e. DOI:10.1007/s00392-020-01626-9.; Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9. DOI:10.1001/jama.2020.6775.; Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. DOI:10.1136/bmj.m1966.; Boytsov SA, Pogosova NV, Paleev FN, et al. Clinical Characteristics and Factors Associated with Poor Outcomes in Hospitalized Patients with Novel Coronavirus Infection COVID-19. Kardiologiia. 2021;61(2):4-14 (In Russ.) [Бойцов С.А., Погосова Н.В., Палеев Ф.Н., и др. Клиническая картина и факторы, ассоциированные с неблагоприятными исходами у госпитализированных пациентов с новой коронавирусной инфекцией COVID-19. Кардиология. 2021;61(2):4-14]. DOI:10.18087/cardio.2021.2.n1532.; Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome coronavirus (MERS) outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J Rehabil Med. 2020;52(5):jrm00063. DOI:10.2340/16501977-2694.; Gaman SA, Ternovoy SK, Pogosova NV, et al. Delayed CT scan of the lungs in patients with COVID19 pneumonia. REJR. 2021;11(1):8-14 (In Russ.) [Гаман С.А., Терновой С.К., Погосова Н.В., и др. Отсроченная КТ легких у пациентов, перенесших COVID-19 пневмонию. REJR. 2021;11(1):8-14]. DOI:10.21569/2222-7415-2021-11-1-8-14.; Perez T, Burgel PR, Paillasseur J, et al. Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. Int J Chron Obst Pulm Disease. 2015;10(1):1663-72. DOI:10.2147/COPD.S82408.; "Temporary Methodological Guideline "Medical Rehabilitation for New Coronavirus Infection (COVID19). Version 2 (31.07.2020)" (approved by the Ministry of Health of Russia) [cited 2022 Jan 10]. Available from: https://xn--80aesfpebagmfblc0a.xn--p1ai/ai/doc/461/attach/28052020_Preg_ COVID-19_v1.pdf (In Russ.) ["Временные методические рекомендации "Медицинская реабилитация при новой коронавирусной инфекции (COVID-19). Версия 2 (31.07.2020)" (утверждены Минздравом России) [цитировано 10.01.2022]. Доступно на: https://xn--80aesfpebagmfblc0a.xn--p1ai/ai/doc/461/attach/28052020_Preg_COVID-19_v1.pdf].; Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428-46. DOI:10.1183/09031936.00150314.; Bubnova MG, Persiyanova-Dubrova AL. Six-minute walk test in cardiac rehabilitation. Cardiovascular Therapy and Prevention. 2020;19(4):2561 (In Russ.) [Бубнова М.Г., Персиянова-Дуброва А.Л. Применение теста с шестиминутной ходьбой в кардиореабилитации. Кардиоваскулярная Терапия и Профилактика. 2020;19(4):2561]. DOI:10.15829/1728-8800-2020-2561.; Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1384-7. DOI:10.1164/ajrccm.158.5.9710086.; Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. DOI:10.1093/eurheartj/ehw106.; Giannis D, Allen SL, Tsang J, et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;137(20):2838-47. DOI:10.1182/blood.2020010529.; Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. DOI:10.1136/bmj.n693.; Leijte WT, Wagemaker NMM, van Kraaij TD, et al. Mortality and re-admission after hospitalization with COVID-19. Ned Tijdschr Geneeskd. 2020;164:D5423.; Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARSCoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568. DOI:10.1001/jamanetworkopen.2021.28568.; Venturelli S, Benatti SV, Casati M, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiol Infect. 2021;149:e32. DOI:10.1017/S0950268821000145.; Tansey CM, Louie M, Loeb M, et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med. 2007;167(12):1312-20. DOI:10.1001/archinte.167.12.1312.; Huang С, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32 DOI:10.1016/S0140-6736(20) 32656-8.; Carfì A, Bernabei R, Landi F, et al. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020; 324(6):603-5. DOI:10.1001/jama.2020.12603.; Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93(2):1013-22. DOI:10.1002/jmv.26368.; Liang L, Yang B, Jiang N, et al. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci. 2020;35(47):e418. DOI:10.3346/jkms.2020.35.e418.; D’Cruz RF, Waller MD, Perrin F, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res. 2021;7(1):00655-02020. DOI:10.1183/23120541.00655-2020.; Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID19-related hospitalisations. Thorax. 2021;76(4):402-4. DOI:10.1136/thoraxjnl-2020-216308.; https://www.rpcardio.com/jour/article/view/2705

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2705
https://doi.org/10.20996/1819-6446-2022-04-03

Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile ; Долгосрочные результаты терапии рассеянного склероза окрелизумабом: клиническая и МРТ-эффективность и профиль безопасности

Συγγραφείς: D. L. Klabukova, M. V. Davydovskaya, Д. Л. Клабукова, М. В. Давыдовская

Πηγή: Meditsinskiy sovet = Medical Council; № 9 (2019); 64-71 ; Медицинский Совет; № 9 (2019); 64-71 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-9

Θεματικοί όροι: долгосрочные результаты, multiple sclerosis, efficacy, safety, long-term outcomes, рассеянный склероз, эффективность, безопасность

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/3036/2961; Dargahi N., Katsara M., Tselios T., Androutsou M.E., de Courten M., Matsoukas J., Apostolopoulos V. Multiple sclerosis: immunopathology and treatment update. Brain Sci. 2017;7(7):78.; Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R. , Sørensen P.S., Thompson A.J., et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83:278–286.; Atlas of MS 2013: Mapping Multiple Sclerosis Around th e World. London [Электронный ресурс]: Multiple Sclerosis International Federation; 2013. URL: https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Дата доступа: 25.02.2019.; Бойко А.Н., Смирнова Н.Ф., Золотова С.Н., Гусев Е.И. Эпидемиология и этиология рассеянного склероза. Consilium Medicum.2008;10(7):5-8. [Boyko A.N., Smirnova N.F., Zolotova S.N., Gusev E.I. Epidemiology and etiology of multiple sclerosis. Consilium Medicum. 2008;10(7):5-8.] (In Russ).; Naci H., Fleurence R., Birt J., Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010;28(5):363-79.; Государственный реестр лекарственных средств [Электронный ресурс]: Инструкция по медицинскому применению лекарственного препарата окрелизумаб (Окревус®). URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = 1e285065-d8dd-4438-b4f8-6358eced347c&t. Дата доступа: 25.02.2019. [State Register of Drugs [Electronic resource]: Patient Information Leaflet for Ocrelizumab (Ocrevus®). URL: https://grls.ros-minzdrav.ru/Grls_View_v2.aspx?routingGuid =1e285065-d8dd-4438-b4f8-6358eed347c&t. Accessed date: 02/25/2019.] (In Russ).; Gasperi C., Stüve O., Hemmer B. B cell-directed therapies in multiple sclerosis. Neurodegener Dis Manag. 2016;6(1):37-47.; Montalban X., Hauser S.L, Kappos L., Arnold D.L., Bar-Or A., Comi G., et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220.; Hauser S.L., Bar-Or A., Comi G., Giovannoni G., Hartung H.P., Hemmer B., et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Scler osis. N Engl J Med. 2017 Jan 19;376(3):221-234.; FDA [Электронный ресурс]: Highlights of prescribing information OCREVUSTM(ocrelizumab), 2017. URL: https://www.accessdata.fda.gov /drugsatfda_docs/label/2017/761053lbl.pdf. Дата доступа: 25.02.2019.; EMA [Электронный ресурс]: Assessment report. Ocrevus, 2018. URL: https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf. Дата доступа: 25.02.2019.; Распоряжение Правительства РФ от 10.12.2018 №2738-р «Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов на 2019 год, а также перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». [Order of the Government of the Russian Federation No. 2738-p «On approval of list of vital and essential drugs, as well as lists of drugs for medical use and the minimum range of drugs required for medical care in 2019» of December 10, 2018] (In Russ).; Roche data on file (ph35s6nd5b2454r5lmkpvk-8gho).; Wolinsky J., Montalban X., Hauser S., et al. Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: Findings from the phase III ORATORIO study extended control period. 7th Joint ECTRIMS and ACTRIMS Meeting, Paris, France; October 25–28, 2017. ECTRIMS/ACTRIMS Poster #P1234.; Kuhelj R., Deol-Bhullar G., Garas M., et al. Openlabel Phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in Relapsing MS and Primary Progressive MS. 2nd Congress of the EAN, Copenhagen, Denmark; May 28–31, 2016. EAN Poster #P11192.; Wolinsky J., Brochet B., Montalban X ., et al. Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. 34th Congress of the ECTRIMS, Berlin, Germany; October 10–12, 2018. ECTRIMS Poster.; Wolinsky J., Arnold D.L., Bar-Or A. Efficacy of ocrelizumab in pati ents with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial. ACTRIMS, New Orleans, Louisiana; February 18–20, 2016. ACTRIMS Poster #LB148.; Elliott C., Wolinsky J., Hauser S., et al. Ocrelizumab may reduce tissue damage i n chronic active lesions as measured by change in T1 hypointensity of slowly evolving lesions in patients with primary progressive multiple sclerosis. AAN Annual Meeting, Los Angeles, CA; April 21–27, 2018. AAN Poster #376.; Turner B., Cree B.A.C., Kappos L., Montalban X., Papeix C., Wolinsky J.S., et al. Ocrelizumab efficacy in subg roups of patients with relapsing multiple sclerosis. J Neurol. 2019 Feb 28. doi:10.1007/s00415-019-09248-6. [Epub ahead of print].; Hauser S., Brochet B., Montalban X., et al. LongTerm reduction of relapse rate and confirmed disability progression after 5 ye ars of ocrelizumab treatment in patients with relapsing multiple sclerosis. 34th Congress of the ECTRIMS, Berlin, Germany; October 10–12, 2018. ECTRIMS Poster.; Arnold D., Kappos L., Hauser S., et al. Long-Term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in p atients with relapsing multiple sclerosis. 34th Congress of the ECTRIMS, Berlin, Germany; October 10–12, 2018. ECTRIMS Poster.; Traboulsee A., Arnold D., Klawiter E., et al. Association of Brain Volume Loss and NEDA Outcomes in Patients With Relap sing Multiple Sclerosis in the OPERA I and OPERA II Studies. 7th Joint ECTRIMS/ACTRIMS Meeting, Paris, France; October 25–28, 2017. ECTRIMS/ACTRIMS Poster #P774.; Hauser S., Kappos L., Montalban X., et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with rel apsing and primary progressive multiple sclerosis. 34th Congress of the ECTRIMS, Berlin, Germany; October 10–12, 2018. ECTRIMS Poster.; Vermersch P., Harp C., Herman A., et al. T-Cell Population Changes and Serious Infection Rates in the Controlled Periods of the Pivotal Phas e III Trials of Ocrelizumab in Multiple Sclerosis. 7th Joint ECTRIMS/ACTRIMS Meeting, Paris, France; October 25–28, 2017. Poster #P668.; Roche data on file (a8u9eabn8dkk545jmeoqn-9bsek).; de Seze J., Hauser S., Kappos L., et al. InfusionRelated Reactions With Ocrelizumab in th e Phase III Studies. 7th Joint ECTRIMS/ACTRIMS Meeting, Paris, France; October 25–28, 2017. ECTRIMS/ACTRIMS Poster #EP1671.; Conte W.L., Arndt N., Cipriani V.P., Dellaria A., Javed A. Reduction in ocrelizumab-induced infusion reactions by a modified premedication pro tocol. Mult Scler Relat Disord. 2019;27:397-399.; Mayer L., Kappos L., Racke M., et al. Infusionrelated reactions with ocrelizumab: pooled analysis of the open-label extension of the Phase III, Interferon beta-1a-controlled OPERA studies. Annual Meeting CMSC, New Orleans, LA; May 24–27, 2017. CMSC Poster #DX44.; Belcher S., Edwards K., Williams T., et al. Reduction of infusion related reactions during ocrelizumab infusions in a comprehensive multiple sclerosis Care Center. 34th Congress of the ECTRIMS, Berlin, Germany; October 10–1 2, 2018. ECTRIMS Abstract #P1257.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/3036
https://doi.org/10.21518/2079-701X-2019-9-64-71

Реканализация хронических окклюзий коронарных артерий с использованием ретроградного подхода: непосредственная и долгосрочная эффективность и факторы влияния на успех процедуры

Πηγή: Дальневосточный медицинский журнал.

Θεματικοί όροι: ХРОНИЧЕСКАЯ ОККЛЮЗИЯ КОРОНАРНОЙ АРТЕРИИ, ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА, РЕТРОГРАДНАЯ РЕКАНАЛИЗАЦИЯ, ДОЛГОСРОЧНЫЕ РЕЗУЛЬТАТЫ, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article_covers/15338539.png
http://cyberleninka.ru/article/n/rekanalizatsiya-hronicheskih-okklyuziy-koronarnyh-arteriy-s-ispolzovaniem-retrogradnogo-podhoda-neposredstvennaya-i-dolgosrochnaya